Compare COOK & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | TNYA |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 153.2M |
| IPO Year | 2021 | 2021 |
| Metric | COOK | TNYA |
|---|---|---|
| Price | $49.20 | $0.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $53.00 | $5.33 |
| AVG Volume (30 Days) | 24.1K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.53 |
| 52 Week High | $86.59 | $2.35 |
| Indicator | COOK | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 32.47 |
| Support Level | $39.02 | $0.62 |
| Resistance Level | $77.25 | $0.82 |
| Average True Range (ATR) | 2.54 | 0.03 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 21.25 | 4.00 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.